Fasting hyperglycemia, a prominent finding in diabetes, is primarily due to increased gluconeogenesis. The transcription factor Foxo1 links insulin signaling to decreased transcription of PEPCK and glucose-6-phosphatase (G6Pase) and provides a possible therapeutic target in insulin-resistant states. Synthetic, optimized antisense oligonucleotides (ASOs) specifically inhibit Foxo1 expression. Here we show the effect of such therapy on insulin resistance in mice with diet-induced obesity (DIO). Reducing Foxo1 mRNA expression with ASO therapy in mouse hepatocytes decreased levels of Foxo1 protein and mRNA expression of PEPCK by 48 ؎ 4% and G6Pase by 64 ؎ 3%. In mice with DIO and insulin resistance, Foxo1 ASO therapy lowered plasma glucose concentration and the rate of basal endogenous glucose production. In addition, Foxo1 ASO therapy lowered both hepatic triglyceride and diacylglycerol content and improved hepatic insulin sensitivity. Foxo1 ASO also improved adipocyte insulin action. At a tissue-specific level, this manifested as improved insulinmediated 2-deoxyglucose uptake and suppression of lipolysis. On a whole-body level, the result was improved glucose tolerance after an intraperitoneal glucose load and increased insulin-stimulated whole-body glucose disposal during a hyperinsulinemic-euglycemic clamp. In conclusion, Foxo1 ASO therapy improved both hepatic insulin and peripheral insulin action. Foxo1 is a potential therapeutic target for improving insulin resistance. Diabetes 55:
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Foxo1 has significant roles in extra hepatic tissues. Foxo1-null mice die in utero, suggesting that Foxo1 is involved in coordinating several key components of development (8) . Overexpression of Foxo1 in myocytes leads to muscle atrophy (9) and insulin resistance, and overexpression in adipocytes impairs adipocyte differentiation (10) . Specifically, Foxo1 coordinates (directly and indirectly) the expression of several genes, including pancreatic duodenal homeobox-1 (11) in ␤-cells, pyruvate dehydrogenase kinase 4 (12) , lipoprotein lipase (13) , adiponectin receptors (14) in muscles, and peroxisome proliferatoractivated receptor (PPAR)-␥ and GLUT4 in adipocytes (10) .
The pivotal role of Foxo1 in glucose metabolism makes it an attractive target for pharmacological intervention. Antisense oligonucleotides (ASOs) accumulate and cause reduction of target expression in specific tissues such as liver and fat (but not skeletal or cardiac muscle) and thus may be used to validate therapies disrupting Foxo1 activity. This essentially mimics insulin action at a transcriptional level and may bypass the defects in insulin signaling seen with intracellular lipid accumulation. Reduction of Foxo1 expression is hypothesized to reduce hepatic gluconeogenesis, improve hepatic insulin action, and enhance peripheral insulin-stimulated glucose metabolism. In the present set of studies, we use ASOs to specifically inhibit Foxo1 in lean, insulin-sensitive mice and obese, insulinresistant mice and assess the subsequent effects on insulin action and glucose metabolism. We performed hyperinsulinemic-euglycemic clamps to assess insulin-stimulated glucose metabolism in liver, muscle, and adipose tissue in mice treated with Foxo1 ASO.
RESULTS

Screening of Foxo1 ASOs in vitro.
Eighty ASOs targeting the Foxo1 mRNA were assayed in vitro for their ability to inhibit Foxo1 mRNA expression. This method of screening ASOs has been described previously and produces potent and specific ASOs (15) . After extensive doseresponse characterization of the most potent ASOs from the screen, one lead ASO, ISIS 188764, was chosen. This ASO sits within the coding region of the Foxo1 mRNA and has no significant cross-reactivity to other Foxo family members. When assayed in a dose-dependent manner in primary mouse hepatocytes, a potent reduction of the Foxo1 mRNA levels was observed (Fig. 1A) . A control ASO, ISIS 141923, composed of the same chemistry and oligonucleotide length, had no effect on Foxo1 mRNA expression in the same study. This reduction of mRNA levels was specific for Foxo1, as other closely related Foxo family members (Foxo3 and Foxo4) remain unaffected by the ASO treatment (Fig. 1B) . A significant reduction of Foxo1 protein was seen 48 -60 h after ASO treatment (Fig. 1C) . The kinetics of protein reduction were far longer than that of mRNA reduction (maximal reduction by 6 -12 h), due to the time required for previously made protein to decay.
Foxo1 has been established as a key regulator of metabolic gene expression in many in vitro and in vivo model systems, relying mainly on overexpression of normal or mutant forms of Foxo1 protein. To determine if inhibition of endogenous Foxo1 protein with an ASO would have similar gene regulation effects, primary mouse hepatocytes were treated with Foxo1 ASO and then stimulated with glucagon to induce the level of key gluconeogenic genes (Fig. 1D ). PEPCK and G6Pase-catalytic, two gluconeogenic genes that are critical for hepatic glucose production, were both significantly decreased by Foxo1 ASO treatment. Specifically, there was a 48 Ϯ 4% suppression of PEPCK mRNA and a 64 Ϯ 3% suppression of G6Pase mRNA with Foxo1 ASO treatment compared with 8 Ϯ 6 and 13 Ϯ 7% suppression for PEPCK and G6Pase, respectively, with control ASO treatment (Fig. 1D) . Efficacy of Foxo1 ASO in vivo. Chronic high-fat feeding in C57BL/6 mice results in diet-induced obesity (DIO) with hyperglycemia and hyperinsulinemia. In association with these metabolic changes, DIO increased hepatic Foxo1 expression (100 Ϯ 12 vs. 263 Ϯ 40 arbitrary units for lean [n ϭ 16] and DIO [n ϭ 15], respectively, P ϭ 0.0005). The association between insulin resistance and increased Foxo1 expression in mice with DIO provides a model system to test the hypothesis that inhibition of Foxo1 with ASO treatment will improve insulin sensitivity in insulinresistant states. The design of the treatment course was guided by previous studies and pilot data demonstrating that ASO therapy at 50 mg ⅐ kg Ϫ1 ⅐ week Ϫ1 is both safe and effective in mice. In addition, 3-4 weeks of ASO therapy is required to achieve the maximal stable inhibition of a transcript of interest. In the present set of experiments, normal lean and high-fat-fed C57BL/6 mice were treated with Foxo1 ASO for 4 -5 weeks to demonstrate that Foxo1 ASO was active in vivo. Within each diet group, there was no difference in body weight between the three treatment arms. Serum transaminase concentrations, as surrogates of hepatotoxicity, over 4 weeks of therapy were not significantly different from basal concentrations ( Table 1) . While there were dose-dependent decreases in the expression of Foxo1 mRNA, the differences were most marked at the 50-mg ⅐ kg Ϫ1 ⅐ week Ϫ1 dose of Foxo1 ASO (data not shown). As shown in Fig. 2A , Foxo1 ASO therapy decreased Foxo1 liver mRNA by 33 Ϯ 6 and 37 Ϯ 6% in both lean and DIO mice, respectively, and Foxo1 fat mRNA by 19 Ϯ 8 and 65 Ϯ 5% (data not shown). This was associated with decreases in hepatic PEPCK in both groups (47 Ϯ 5 and 62 Ϯ 3% for lean and DIO group, respectively) and G6Pase in the lean group (48 Ϯ 4%; Fig. 2B and C) . In contrast, G6Pase expression was not significantly altered by Foxo1 ASO treatment in the DIO group. Effect of Foxo1 ASO on glucose and insulin concentration. In lean mice, Foxo1 ASO therapy was not associated with any significant change in fed blood glucose levels (Fig. 3A) ; however, it did result in a lowering of plasma insulin levels by 55 Ϯ 9% after 4 weeks of treatment (Fig. 3C ). In the DIO group, where fed blood glucose level was comparatively higher, Foxo1 ASO therapy led to a significant reduction by 34 Ϯ 3% after 4 weeks of treatment (Fig. 3B) . Moreover, this reduction in fedglucose levels occurred with a simultaneous 87 Ϯ 3% reduction in plasma insulin concentration (Fig. 3D) . Finally, Foxo1 ASO therapy improved clearance of glucose after an intraperitoneal glucose load in both the lean and DIO groups ( Fig. 3E and F) . The decreases in glucose and insulin levels and improvements in glucose clearance after a glucose load suggest that inhibition of endogenous Foxo1 affects both hepatic and peripheral insulin action. Effect of Foxo1 on hepatic insulin action. Discerning the impact of Foxo1 ASO therapy on peripheral and hepatic insulin action was accomplished with hyperinsulinemic-euglycemic clamps. These were performed on 20-week-old mice that were fed either a standard control diet (lean) or a high-fat diet (DIO) for 16 weeks and received saline, control ASO, or Foxo1 ASO therapy twice weekly for 4 weeks. The two diet groups had significantly different weights but, within each diet group, the weights were identical between treatment arms (28.8 Ϯ 0.5 vs. 29.88 Ϯ 0.6 vs. 29.5 Ϯ 0.5 g for lean saline-, control ASO-, and Foxo1 ASO-treated mice, respectively, and 45.8 Ϯ 0.7 vs. 46.8 Ϯ 0.5 vs. 46.2 Ϯ 0.9 g for DIO saline-, control ASO-, and Foxo1 ASO-treated mice, respectively). At the end of the treatment period, the mice underwent a hyperinsulinemic-euglycemic clamp study at 2.5 mU ⅐ kg Ϫ1 ⅐ min
Ϫ1
insulin infusion with 2-deoxyglucose (2-DG) infusion to assess tissue-specific glucose uptake. Comparing endogenous glucose production (EGP) under basal and clamped conditions assesses hepatic insulin sensitivity ( Fig. 4A and B). Comparisons of insulin-stimulated whole-body glucose utilization (R d ) and tissue-specific 2-DG uptake provides a complementary assessment of peripheral insulin action.
As shown in Previous studies have shown that tissue fat metabolites correlate closely with hepatic insulin resistance. As expected, in comparing the lean and DIO groups, chronic high-fat feeding led to an approximate threefold increase in liver triglyceride (TG) content. As seen in Fig. 4C , Foxo1 ASO therapy did not alter liver TG content in the lean group (20 Ϯ 4 vs. 17 Ϯ 4 vs. 14 Ϯ 3 mg/g liver for saline, control ASO, and Foxo1 ASO, respectively, ANOVA P ϭ 0.58). In contrast, in the DIO group, Foxo1 ASO therapy normalized liver TG content to nearly that of the lean group (Fig. 4D , 46 Ϯ 2 vs. 65 Ϯ 11 vs. 23 Ϯ 4 mg/g for saline, control ASO, and Foxo1 ASO, respectively, P Ͻ 0.01 for control ASO vs. Foxo1 ASO). This decrease in liver TG occurred in the absence of any significant differences in body weight or percent fat mass as assessed by 1 H magnetic resonance spectroscopy (43.4 vs. 45.5 vs. 45.0% for saline, control ASO, and Foxo1 ASO, respectively). The fat metabolites were further analyzed by LC/MS/MS (liquid chromatography/mass spectrometry/mass spectrometry) to distinguish differences in diacylglycerol (DAG) and fatty acyl CoA species (Fig. 4E ). Hepatic DAG content mirrored hepatic TG content. The expected increase in DAG concentration with high-fat feeding was reversed with Foxo1 ASO treatment (Fig. 4E) . The total DAG contents in the lean group were 18.6 Ϯ 2.6 vs. 13.1 Ϯ 3.7 vs. 11.0 Ϯ 0.6 mol/g liver (ANOVA P ϭ 0.16) for the saline, control ASO, and Foxo1 ASO, respectively. The total DAG content for the DIO group was 32.1 Ϯ 3.3 vs. 32.5 Ϯ 4.7 vs. 12.9.2 Ϯ 4.1 mol/g liver (Fig. 4E, inset) for the saline, control ASO, and Foxo1 ASO groups, respectively (P Ͻ 0.05 vs. saline and Ͻ0.01 vs. control ASO). In analyzing the profile of the constituent DAGs, the DIO group showed a predominance of DAG species containing oleic acid (i.e., OO and OL) and palmitic acid (i.e., PL). This reflects the predominance of oleic acid and palmitic acid in lard, the major dietary fat provided to the DIO mice. The concentration for most of ⅐ min Ϫ1 for saline and control ASO, respectively) mice. Foxo1 ASO therapy resulted in modest improvements in peripheral glucose metabolism in both diet groups, although this difference only achieved statistical significance in the DIO group. To better understand the mechanism for the increased peripheral glucose metabolism, tissue-specific 2-DG uptake was measured. There was no statistically significant difference in gastrocnemius 2-DG (Fig. 5B) 30.9 Ϯ 6.24% suppression for saline, control ASO, and Foxo1 ASO, respectively, for DIO mice, P Ͻ 0.01 vs. control ASO; Fig. 5D ). In summary, Foxo1 ASO therapy was associated with modest improvements in peripheral insulin action that appear to largely be accounted for by increases in adipose insulin sensitivity.
DISCUSSION
Insulin-mediated phosphorylation of Foxo1, via AKT2, leads to Foxo1 nuclear exclusion and degradation. Therefore, reducing Foxo1 mRNA expression using specific ASOs should echo insulin action at a transcriptional level. Reduction of Foxo1 expression has the potential to remedy many of the defects seen in insulin-resistant states by mimicking insulin action in the nucleus despite acquired cytoplasmic defects in the insulin signaling cascade. The studies presented in this manuscript validate the therapeutic potential for Foxo1 inhibition in two key insulin-target tissues (liver and adipose tissue) and quantitate this effect. First, ASOs designed against Foxo1 lower Foxo1 mRNA and protein levels and, in turn, lower expression of gluconeogenic enzymes. Second, these changes lower endogenous glucose production and, as a consequence, lower glucose and insulin concentrations. Third, Foxo1 ASO therapy normalized hepatic lipid concentration in DIO mice and improved hepatic insulin action. Finally, Foxo1 ASO therapy improved insulin-stimulated white adipocyte glucose uptake without any discernible effect on muscle glucose uptake.
From a pool of ϳ80 synthetic oligonucleotides designed against Foxo1 mRNA, a single-lead ASO was chosen for in vivo studies based on its potency in both in vitro and in vivo screens. In vitro, this ASO demonstrated a dosedependent decrease in Foxo1 mRNA and Foxo1 protein levels without any change in the expression of Foxo3 and Foxo4, two related transcription factors. Moreover, the decrease in Foxo1 mRNA was associated with a decrease in PEPCK and G6Pase mRNA expression. This same ASO was tested in two relevant mouse models, one lean and one obese (DIO).
Interestingly, with DIO, there was an increase in Foxo1 mRNA and protein levels in the liver. The mechanism for this increase with fat feeding is not clear but suggests an association between diet-induced insulin resistance and increases in Foxo1. Treatment with Foxo1 ASO at a dose of 50 mg ⅐ kg Ϫ1 ⅐ week Ϫ1 led to a 20 -40% decrease in Foxo1 mRNA levels. Physiologically, Foxo1 inhibition markedly decreased fasting insulin in the DIO group with a ϳ15% decrease in the rate of EGP and ϳ20% decrease in fasting plasma glucose. This decrease in EGP and fasting glucose appears to be primarily achieved by the 50% decrease in PEPCK without any significant suppression of G6Pase. These findings demonstrate that a proximal block in the gluconeogenic pathway is sufficient to decrease EGP and lower fasting plasma glucose. The finding that G6Pase expression was not significantly altered in DIO mice treated with Foxo1 ASO suggests that other factors (i.e., HNF4, glucocorticoids, LXR) may eclipse Foxo1 inhibition in driving G6Pase transcription.
In addition to the changes in basal hepatic glucose metabolism, Foxo1 ASO therapy improved hepatic insulin sensitivity. The present data show that Foxo1 ASO treatment resulted in a nonsignificant trend toward increased suppression of EGP in the lean group (ϳ25%) and a significant suppression of EGP by 50% in the DIO group. One possible explanation for the increased hepatic insulin responsiveness seen with Foxo1 ASO treatment in the DIO group is that the lowering of intrahepatic lipid content improved hepatic insulin action. Previous studies have 
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shown that changes in intrahepatic fat content correlate inversely with hepatic insulin action (16 -21) . In the present study, Foxo1 ASO therapy decreased hepatic TG and DAG content in the DIO mice to levels approaching those of the lean mice and, as a consequence, improved hepatic insulin action.
Foxo1 inhibition led to modest improvements in peripheral insulin action as well. Foxo1 ASO therapy decreased 
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the excursion of blood glucose in response to an intraperitoneal glucose load, suggesting improved whole-body clearance of glucose. This was confirmed with the hyperinsulinemic-euglycemic clamp, where Foxo1 ASO therapy increased peripheral glucose metabolism by ϳ15% in the lean group and ϳ20% in the DIO group. Finally, in analyzing tissue-specific 2-DG uptake, there was ϳ40% and ϳ100% increase in epididymal WAT glucose uptake with Foxo1 ASO therapy in the DIO and lean groups, respectively. Foxo1 ASO therapy nearly normalized the impaired insulin-stimulated WAT glucose uptake in the DIO group. Dowell et al. (22) described an antagonistic relationship between Foxo1 and PPAR-␥ where Foxo1 decreased the formation of a PPAR-␥/RXR/DNA complex. Therefore, reducing Foxo1 mRNA expression may lead to improvements in PPAR-␥ activity. However, in the present study, the expression of PPAR-␥ target genes (aP2, ACS, and FATP) in epididymal adipose tissue was unaffected by Foxo1 ASO treatment, suggesting that other mechanisms may be at work (data not shown). The absence of any improvements in muscle insulin action may reflect the ability of ASOs to accumulate in liver and adipose as opposed to muscle (23) . Thus, Foxo1 ASO therapy results in modest improvements in peripheral insulin action, mainly through improvements in adipose tissue insulin response, which may be a result of improved PPAR-␥ activity.
These results are consistent with previous studies by Nakae et al. (24) , in which Foxo1 haploinsufficient mice were crossed with mice lacking the insulin receptor, and by Altomonte et al. (7) , in which db/db mice were treated with an adenovirus expressing a dominant-negative mutant of Foxo1. In both studies, decreasing Foxo1 action lowered levels of PEPCK and G6Pase mRNA and lowered blood glucose concentration. The present set of studies build on this previous work by measuring organ-specific insulin action and quantifying changes in glucose flux in mice made insulin resistant by chronic high-fat feeding. First, DIO is associated with elevations in hepatic Foxo1. Second, modest inhibition (ϳ40% knockdown) of endogenous Foxo1 is sufficient to lower basal EGP and blood glucose and insulin levels and improve hepatic insulin action under hyperinsulinemic conditions. Finally, Foxo1 inhibition also improved adipocyte insulin action. While we were unable to detect any significant differences in the expression key genes (adipose tissue GLUT4, adiponectin, adiponectin receptor, and tumor necrosis factor-␣), we did measure increases in insulin-stimulated glucose uptake and suppression of lipolysis. In conclusion, the studies here support the hypothesis that therapies aimed at reducing endogenous Foxo1 expression will improve glucose homeostasis in insulin-resistant states. Moreover, the salutary effects of Foxo1 extend beyond its ability to reduce EGP and include a reduction of hepatic steatosis and an increase in adipocyte insulin responsiveness.
RESEARCH DESIGN AND METHODS
All mice were maintained in accordance with the institutional Animal Use and Care Committees of Amgen and Yale University School of Medicine. C57BL/6 mice were obtained at 3-4 weeks of age from Charles River Laboratories 
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(Wilmington, MA) and acclimated for 1 week after arrival and before initiation of the experiment. Mice received food and water ad libitum and were maintained on a 12:12-h light-dark cycle (lights on at 6:30 A.M.). Mice were housed five per cage for the first 8 weeks of the feeding regimen and single-housed for 4 weeks before initiation of treatment. From a cohort of 100 mice, 80 were started on a high-fat diet (Research Diets D12492) at 3 weeks of age for 12 weeks. The remaining 20 mice were kept on a normal rodent diet. Body weight was monitored, and mice were randomized on blood glucose values and body weight before starting the treatment. Blood samples (ϳ150 l) were collected by retroorbital bleed into EDTA plasma tubes before the initiation of the ASO or saline treatment of each study and every other week after the treatment was started. Blood glucose was measured using a OneTouch Profile glucometer (LifeScan, Milpitas, CA). All ASOs (control and Foxo1) were prepared in normal saline, and the solutions were sterilized through a 0.2-m filter. Mice in each diet group were dosed with ASO solutions or saline twice per week via intraperitoneal injection at a dose of 50 mg ⅐ kg Ϫ1 ⅐ week Ϫ1 . This dose was chosen on the basis of pilot studies showing it to the be most efficacious, nontoxic dose with regards to suppression of Foxo1 mRNA. During the treatment period, body weight and food intake were measured weekly. Selection of murine Foxo1 ASO. Rapid-throughput screens were performed in vitro to identify a murine Foxo1-selective ASO inhibitor as previously described (15) . In brief, 80 ASOs were designed to the mouse Foxo1 mRNA sequence. All ASOs were synthesized as 20-base phosphorothioate chimeric ASOs, where bases 1-5 and 16 -20 were modified with 2Ј-O-(2-methoxy)-ethyl. This chimeric design has been shown to provide both increased nuclease resistance and mRNA affinity, while maintaining the robust RNase H terminating mechanism utilized by these types of ASOs (25) . These benefits result in an attractive in vivo pharmacological and toxicological profile for 2Ј-O-(2-methoxy)-ethyl chimeric ASOs. The ASOs were screened in mouse primary hepatocytes for their ability to inhibit Foxo1 mRNA expression. The final-lead mouse Foxo1 ASO, ISIS 188764, was selected after detailed characterization in vitro and in silico. ISIS 188764 has the sequence 5Ј-TCCAGTTCCTTCATTCTGCA-3Ј and hybridizes to position 10961-115 on Genbank accession no. AJ252157.1. The control ASO, ISIS 141923, has the sequence 5Ј-CCTTCCCTGAAGGTTCCTCC-3Ј and does not have perfect complementarity to any known gene in public databases. In vitro treatment of primary hepatocytes with Foxo1 ASOs. Primary murine hepatocytes were isolated, as previously described, and plated onto collagen-coated plates (26) . Hepatocytes were treated with ASO and Lipofectin (Invitrogen) mixture for 4 h in serum-free William's E media (Invitrogen). ASO and Lipofectin were mixed at a ratio of 3 g Lipofectin for every 1 ml of 100-nmol/l ASO concentration. After 4 h, ASO reaction mixture was replaced with normal maintenance media (William's E media with 10% fetal bovine serum [FBS] ) and the cells incubated under normal conditions for indicated times (generally, 20 -24 h for RNA and 60 h for protein). Analysis of Foxo1 mRNA from in vitro samples. Total RNA was extracted from cells using the RNeasy 96-kit (Qiagen, Valencia, CA) as per manufacturer's protocol. RT-PCR analysis of Foxo1 and other mRNAs was performed using an ABI Prism 7700 Sequence Detector (Applied Biosystems, Foster City, CA) as described previously (27) . Briefly, 100 ng total RNA was analyzed in a final volume of 25 l containing 200 nmol/l gene-specific PCR primers, 0.2 mmol/l each dNTP, 75 nmol/l fluorescently labeled oligonucleotide probe, 1ϫ RT-PCR buffer, 5 mmol/l MgCl 2 , 2 units Platinum TaqDNA polymerase (Invitrogen), and 8 units ribonuclease inhibitor. Reverse transcription was performed for 30 min at 48°C followed by PCR: 40 thermal cycles of 30 s at 94°C and 1 min at 60°C. All expression data were normalized to a Ribogreen (Molecular Probes) value, which is a measurement of total RNA. Primer-probe sets were synthesized by IDT (Coralville, IA), with the probes synthesized with FAM-TAM fluorophores. The following primer-probe sets were used for mRNA expression analysis: Foxo1: forward primer CAAAGTACACATACGGC CAATCC, reverse primer CGTAACTTGATTTGCTGTCCTGAA, probe TGAGC CCTTTGCCCCAGATG CCTAT. Foxo3: forward primer AACAGACCAGCCAC CTTCTCTT, reverse primer TGAAGCAAGCAGGTCTTGGA, probe CGTGTCA CACTACGGCAA CCAGACA. Foxo4: forward primer ATGCTGTTGGAAATGT GAAGTCA, reverse primer CTCAGCTCAGATAAGACTCTCTACAAAAA, probe TGGCCTTACCCCTGCCTTTG. Analysis of Foxo1 protein by Western blot. Total cellular protein was extracted from cells by lysing cells at 4°C with protein extraction buffer (10 mmol/l Tris, pH 7.4, 150 mmol/l NaCl, 2 mmol/l EDTA, 5 mmol/l EGTA, 1% Triton X-100, 0.5% NP-40, 1 mmol/l sodium orthovanadate, 1 mmol/l NaF, and protease inhibitor cocktail tablet [Complete; Roche Diagnostics, Indianapolis, IN]). Extracts were centrifuged at 14,000g at 4°C for 10 min and supernatant saved as total protein lysate. Protein was quantitated using a modified Lowry assay (DC protein assay; Bio-Rad, Hercules, CA). For Western blot detection of individual proteins, 20 -40 g total protein lysate was electrophoresed through 8% Tris-Glycine polyacrylamide gels (Invitrogen, Carlsbad, CA) and then transferred to nylon membrane (Immobilon-P; Millipore, Billerica, MA). Membranes were blocked in 5% nonfat milk (Bio-Rad) for 1 h and then incubated with primary antibody overnight at 4°C. Antibodies used were Foxo1 (0.25 g/ml, 07-176; UBI) and Akt (1:1,000, 9272; Cell Signaling). Membranes were washed with Tris-buffered saline and then incubated with horseradish peroxidase anti-rabbit secondary antibody (1:2,000; UBI) for 1 h. After extensive washing, proteins were visualized using ECL-Plus kit (Amersham, Piscataway, NJ) per the manufacturer's protocol. Membranes were either exposed to film or scanned (Typhoon Scanner; Molecular Dynamics [Amersham Biosciences], Piscataway, NJ) and then quantitated using ImageQuant software. In vitro modulation of metabolic gene expression. Primary mouse hepatocytes were treated with ASO, as described above, and then incubated in normal maintenance (William's E with 10% FBS) media for 48 h. Cells were then incubated in William's E with 0.1% FBS for 12 h, followed by a 1-nmol/l glucagon (Sigma, St. Louis, MO) stimulation for 4 h. RNA was extracted as described above, followed by analysis of metabolic gene expression with RT-PCR as described above. Primer-probe sets were synthesized as described above. PEPCK: forward ATCCAGGGCAGCCTCGA, reverse AGCATTGCC TTCC ACGAACT, probe AGCCTGCCCCAGGCAGTGAGG; G6Pase-catalytic: forward TGCAAGGGAGAACTCAGCAA, reverse GGACCAAGGAAGCCACA ATG, probe TCGTTCCCATTCCGCTTCGCC; FASn: forward CATGACCTCG TGAT GAACGTGT, reverse CGGGTGAGGACGTTTACAAAG, probe CCGT CACT TCCAGTTAGAGCAGGACAAGC. Glucose tolerance test. Mice were fasted from 9:00 P.M. to 9:00 A.M. Blood glucose was measured at 9:00 A.M., and an intraperitoneal glucose bolus (2 g/kg body wt) was administered to conscious, unrestrained mice. Blood glucose was measured at 30 and 90 min after glucose injection using a OneTouch Profile glucometer. To minimize stress levels, 60-and 120-min glucose levels were not measured. Hyperinsulinemic-euglycemic clamp studies. Four days before the hyperinsulinemic-euglycemic studies, mice had body composition assessed by 1 H magnetic resonance spectroscopy (Bruker BioSpin, Billerica, MA). Jugular venous catheters were implanted and the mice allowed to recover for 4 days. After an overnight fast, [3- 3 H]glucose (HPLC purified; Perkin Elmer, Boston, MA) was infused at a rate of 0.05 Ci/min for 2 h to assess the basal glucose turnover. Following the basal period, the hyperinsulinemic-euglycemic clamp was conducted for 120 min with a primed/continuous infusion of human insulin (300-pmol/kg prime, 15-pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 infusion) (Novo Nordisk, Princeton, NJ) and a variable infusion of 20% dextrose to maintain euglycemia (ϳ100 -120 mg/dl). Plasma samples were obtained from the tail at 20, 40, 55, 70, 75, 80, 95, and 120 min [3- 3 H]glucose was infused at a rate of 0.1 Ci/min throughout the clamps and 2-deoxy-D- [1- 14 C]glucose (DOG; Perkin Elmer) was injected as bolus at the 75th min of the clamp to estimate the rate of insulin-stimulated tissue glucose uptake as previously described (28) . At the end of clamp, mice were anesthetized with pentobarbital sodium injection (150 mg/kg), and all tissues were taken within 4 min, frozen immediately using liquid N 2 -cooled aluminum tongs, and stored at Ϫ80°C for later analysis. Biochemical analysis and calculations. Plasma glucose was analyzed during the clamps using 10 l plasma by a glucose oxidase method on a Beckman glucose analyzer II (Beckman, Fullerton, CA). Plasma insulin was measured by radioimmunoassay using a kit from Linco Research (St. Charles, MO). Plasma free fatty acid was determined using an acyl-CoA oxidase-based colorimetric kit (Wako Pure Chemical Industries, Osaka, Japan). For the determination of plasma 3 H-glucose and 14 C-2-DG, plasma was deproteinized with ZnSO 4 and Ba(OH) 2 , dried to remove 3 H 2 O, resuspended in water, and counted in scintillation fluid (Ultima gold; Perkin Elmer) on a Beckman scintillation counter.
Rates of basal and insulin-stimulated whole-body glucose turnover were determined as the ratio of the [3- 3 H]glucose infusion rate (disintegrations per minute [dpm] per minute) to the specific activity of plasma glucose (dpm per mg) at the end of basal period and during the final 30 min of clamp experiment, respectively. Hepatic glucose output was determined by subtracting the glucose infusion rate from the total glucose appearance. For the determination of individual tissue glucose uptake, tissue samples were homogenized and the supernatants subjected to an ion-exchange column to separate tissue 14 C-2-DG-6-phosphate from 14 C-2-DG. Tissue glucose uptake was calculated from area under curve of plasma 14 C-2-DG profile and muscle 14 C-2-DG-6-phosphate content, as previously described (28) . Tissue lipid measurement. The solid-phase extraction and purification of medium, long-chain, and very-long-chain fatty acyl-CoAs from liver have been described previously (29, 30) Total fatty acyl-CoA content is expressed as the sum of individual species. The DAG extraction was performed as previously described (31) . An aliquot of the organic phase was retained for measurement of TG content. This was passed over preconditioned columns (Sep-Pak Cartridge WAT020845; Waters, Milford, MA) to purify the DAG component. Using mass spectrometry the transition pairs ϩ: fatty acids from DAG (Q1 and Q3) were monitored in positive multiple reaction monitor mode for each DAG metabolite. Total DAG content is expressed as the sum of individual species. Tissue TG was extracted using the method of Bligh and Dyer (29) and measured using a DCL Triglyceride Reagent (Diagnostic Chemicals Limited, Charlottetown, Prince Edward Island, Canada). Statistical analyses. All values are expressed as the means Ϯ SE. Comparisons across the three groups were done using one-way ANOVA. When the ANOVA yielded a significant difference, post hoc analysis was done using Tukey's honestly significant difference test.
